Compare TMQ & PHAT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TMQ | PHAT |
|---|---|---|
| Founded | 2004 | 2018 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Precious Metals | Biotechnology: Pharmaceutical Preparations |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 579.8M | 590.6M |
| IPO Year | 2012 | 2019 |
| Metric | TMQ | PHAT |
|---|---|---|
| Price | $1.83 | $5.86 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 6 | 11 |
| Target Price | $6.64 | ★ $20.05 |
| AVG Volume (30 Days) | 1.4M | ★ 1.8M |
| Earning Date | 10-02-2026 | 10-29-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 42.72 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $175,110,000.00 |
| Revenue This Year | N/A | $79.63 |
| Revenue Next Year | N/A | $54.71 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 216.93 |
| 52 Week Low | $1.81 | $5.02 |
| 52 Week High | $7.25 | $18.31 |
| Indicator | TMQ | PHAT |
|---|---|---|
| Relative Strength Index (RSI) | 29.05 | 43.87 |
| Support Level | N/A | $5.03 |
| Resistance Level | $2.35 | $7.72 |
| Average True Range (ATR) | 0.14 | 0.56 |
| MACD | 0.00 | 0.09 |
| Stochastic Oscillator | 0.93 | 41.07 |
Trilogy Metals Inc is an exploration stage company engaged in mineral exploration. The company focuses on exploring and developing its mineral resource properties, which include the Upper Kobuk Mineral Projects (UKMP or UKMP Projects), in the Ambler mining district located in Alaska, the USA. Its properties include the Arctic copper-zinc-gold-silver project and other mineralized targets within a volcanogenic massive sulfide belt, and it also has a bornite carbonate-hosted copper project.
Phathom Pharmaceuticals Inc operates as a clinical-stage biopharmaceutical company. The firm is focused on developing and commercializing novel treatments for gastrointestinal, or GI, diseases. Its product comprises vonoprazan, an oral small-molecule potassium competitive acid blocker medicine that blocks acid secretion in the stomach. Vonoprazan shows rapid, potent, and durable anti-secretory effects and has demonstrated clinical benefits in the treatment of gastroesophageal reflux disease, and in combination with antibiotics for the treatment of Helicobacter pylori infection.